What are the top competitors of DocMorris AG in Healthcare sector?

The top competitors of DocMorris AG in the Healthcare sector are: Bristol-Myers Squibb Company (BMY.SW), Biogen Inc. (BIIB.SW), DocMorris AG (DOCM.SW), Johnson & Johnson (JNJ.SW).

Which has better valuations & earnings, DocMorris AG or its competitors?

DocMorris AG has a market cap of 404.5M and a Dividend Yield of N/A compared to its competitors.

Which stock is more profitable: DocMorris AG or its competitors?

DocMorris AG has an EPS of CHF-15.35, while BMY.SW has an EPS of CHF2.69. So, DocMorris AG is more profitable compared to BMY.SW.

What is DocMorris AG stock volatility and risk in terms of investment?

DocMorris AG has daily volatility of 0% as compared to its competitor BMY.SW which is 0%. DocMorris AG is less volatile as compared to competitors and has low risk.

Is DocMorris AG stock profitable?

DocMorris AG has a Return on Equity (ROE) of -0.29%. So, DocMorris AG is more profitable.

What is DocMorris AG stock’s 52 weeks high and low?

DocMorris AG stock has a 52-week high of (CHF35.02) and a low of (CHF35.02).

What was the average volume of DocMorris AG stock?

The average volume of DocMorris AG is (-) in terms of investment.

DocMorris AG (ROSE.SW) Competitors

DocMorris AG (ROSE.SW) Stock Competitors & Peer Comparison

See (ROSE.SW) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

Symbol	Price	Change %	Market Cap	P/E Ratio	EPS	Dividend Yield
ROSE.SW	CHF 35.02	N/A	404.5M	-2.28	-CHF 15.35	N/A
BMY.SW	CHF 42.54	-4.40%	70.7B	15.81	CHF 2.69	+3.50%
BIIB.SW	CHF 147.46	-36.44%	21.6B	21.69	CHF 6.80	N/A
DOCM.SW	CHF 4.74	-1.25%	230.5M	-1.04	-CHF 4.58	N/A
JNJ.SW	CHF 193.57	+4.86%	0	N/A	N/A	+0.52%

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ROSE.SW vs BMY.SW Comparison March 2026

ROSE.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ROSE.SW stands at 404.5M. In comparison, BMY.SW has a market cap of 70.7B. Regarding current trading prices, ROSE.SW is priced at CHF 35.02, while BMY.SW trades at CHF 42.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ROSE.SW currently has a P/E ratio of -2.28, whereas BMY.SW's P/E ratio is 15.81. In terms of profitability, ROSE.SW's ROE is -0.29%, compared to BMY.SW's ROE of +0.37%. Regarding short-term risk, ROSE.SW and BMY.SW have similar daily volatility (0.00).Check BMY.SW's competition here

DocMorris AG